Preoperative BRAF(V600E) mutation screening is unlikely to alter initial surgical treatment of patients with indeterminate thyroid nodules: A prospective case series of 960 patients

Cancer

Volumn 119, Issue 8, 2013, Pages 1495-1502

  Kleiman, David A ^a   Sporn, Matthew J ^a   Beninato, Toni ^a   Crowley, Michael J ^a   Nguyen, Anvy ^a   Uccelli, Alessia ^a   Scognamiglio, Theresa ^a   Zarnegar, Rasa ^a   Fahey III, Thomas J ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

BRAF(V600E); fine needle biopsy; thyroid neoplasms; thyroid nodule

Indexed keywords

B RAF KINASE; GLUTAMINE; VALINE;

ADULT; ARTICLE; BENIGN TUMOR; BETHESDA CATEGORY; BRAF GENE; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; CYTOLOGY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; FEMALE; GENE IDENTIFICATION; GENETIC CORRELATION; GENETIC MARKER; GENETIC SCREENING; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; THYROID CANCER; THYROID NODULE; THYROID SURGERY; THYROIDECTOMY; TREATMENT PLANNING; TUMOR CLASSIFICATION;

BIOPSY, FINE-NEEDLE; CYTOLOGICAL TECHNIQUES; EARLY DETECTION OF CANCER; FEMALE; GENETIC TESTING; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS B-RAF; RISK FACTORS; THYROID NODULE;

EID: 84876061414     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27888     Document Type: Article

References (39)

1. Dean DS, Gharib H,. Epidemiology of thyroid nodules. Best Pract Res Clin Endocrinol Metab. 2008; 22: 901-911.
2. Yang GC, Liebeskind D, Messina AV,. Ultrasound-guided fine-needle aspiration of the thyroid assessed by Ultrafast Papanicolaou stain: data from 1135 biopsies with a two- to six-year follow-up. Thyroid. 2001; 11: 581-589.
3. Filetti S, Durante C, Torlontano M,. Nonsurgical approaches to the management of thyroid nodules. Nature clinical practice. Endocrinol Metab. 2006; 2: 384-394.
4. Yang J, Schnadig V, Logrono R, Wasserman PG,. Fine-needle aspiration of thyroid nodules: a study of 4703 patients with histologic and clinical correlations. Cancer. 2007; 111: 306-315.
5. ATA adopts TeleHomecare clinical guidelines. Home Healthc Nurse Manag. 1999; 3: 24-25.
6. Cibas ES, Ali SZ,. The Bethesda System for reporting thyroid cytopathology. Thyroid. 2009; 19: 1159-1165.
7. Haugen BR, Woodmansee WW, McDermott MT,. Towards improving the utility of fine-needle aspiration biopsy for the diagnosis of thyroid tumours. Clin Endocrinol (Oxf). 2002; 56: 281-290.
8. Salvatore G, Giannini R, Faviana P, et al. Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab. 2004; 89: 5175-5180.
9. Sapio MR, Posca D, Raggioli A, et al. Detection of RET/PTC, TRK and BRAF mutations in preoperative diagnosis of thyroid nodules with indeterminate cytological findings. Clin Endocrinol (Oxf). 2007; 66: 678-683.
10. Nikiforov YE, Steward DL, Robinson-Smith TM, et al. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab. 2009; 94: 2092-2098.
11. Nikiforov YE, Ohori NP, Hodak SP, et al. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab. 2011; 96: 3390-3397.
12. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009; 19: 1167-1214.
13. Nikiforova MN, Kimura ET, Gandhi M, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab. 2003; 88: 5399-5404.
14. Xing M,. BRAF mutation in thyroid cancer. Endocr Relat Cancer. 2005; 12: 245-262.
15. Xing M, Tufano RP, Tufaro AP, et al. Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. J Clin Endocrinol Metab. 2004; 89: 2867-2872.
16. Tetzlaff MT, LiVolsi V, Baloch ZW,. Assessing the utility of a mutational assay for B-RAF as an adjunct to conventional fine needle aspiration of the thyroid gland. Adv Anat Pathol. 2006; 13: 228-237.
17. Kebebew E, Weng J, Bauer J, et al. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg. 2007; 246: 466-470.
18. Kim TH, Park YJ, Lim JA, et al. The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer. 2012; 118: 1764-1773.
19. Alexander EK, Kennedy GC, Baloch ZW, et al. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N Engl J Med. 2012; 367: 705-715.
20. Keutgen XM, Filicori F, Crowley MJ, et al. A panel of four miRNAs accurately differentiates malignant from benign indeterminate thyroid lesions on fine needle aspiration. Clin Cancer Res. 2012; 18: 2032-2038.
21. Adeniran AJ, Hui P, Chhieng DC, Prasad ML, Schofield K, Theoharis C,. BRAF mutation testing of thyroid fine-needle aspiration specimens enhances the predictability of malignancy in thyroid follicular lesions of undetermined significance. Acta Cytol. 2011; 55: 570-575.
22. Cañadas-Garre M, Becerra-Massare P, Lõpez de la Torre-Casares M, et al. Reduction of false-negative papillary thyroid carcinomas by the routine analysis of BRAF(T1799A) mutation on fine-needle aspiration biopsy specimens: a prospective study of 814 thyroid FNAB patients. Ann Surg. 2012; 255: 986-992.
23. Colanta A, Lin O, Tafe L, et al. BRAF mutation analysis of fine-needle aspiration biopsies of papillary thyroid carcinoma: impact on diagnosis and prognosis. Acta Cytol. 2011; 55: 563-569.
24. Howell GM, Nikiforova MN, Carty SE, et al. BRAF V600E mutation independently predicts central compartment lymph node metastasis in patients with papillary thyroid cancer. Ann Surg Oncol. 2012; doi:10.1245/s10434-012- 2611-0.
25. Joo JY, Park JY, Yoon YH, et al. Prediction of occult central lymph node metastasis in papillary thyroid carcinoma by preoperative BRAF analysis using fine-needle aspiration biopsy: a prospective study. J Clin Endocrinol Metab. 2012; 97: 3996-4003.
26. Kelman AS, Rathan A, Leibowitz J, Burstein DE, Haber RS,. Thyroid cytology and the risk of malignancy in thyroid nodules: importance of nuclear atypia in indeterminate specimens. Thyroid. 2001; 11: 271-277.
27. Goldstein RE, Netterville JL, Burkey B, Johnson JE,. Implications of follicular neoplasms, atypia, and lesions suspicious for malignancy diagnosed by fine-needle aspiration of thyroid nodules. Ann Surg. 2002; 235: 656-662.
28. VanderLaan PA, Marqusee E, Krane JF,. Usefulness of diagnostic qualifiers for thyroid fine-needle aspirations with atypia of undetermined significance. Am J Clin Pathol. 2011; 136: 572-577.
29. Layfield LJ, Morton MJ, Cramer HM, Hirschowitz S,. Implications of the proposed thyroid fine-needle aspiration category of "follicular lesion of undetermined significance": A five-year multi-institutional analysis. Diagn Cytopathol. 2009; 37: 710-714.
30. Shi Y, Ding X, Klein M, et al. Thyroid fine-needle aspiration with atypia of undetermined significance: a necessary or optional category? Cancer. 2009; 117: 298-304.
31. Kato MA, Buitrago D, Moo TA, et al. Predictive value of cytologic atypia in indeterminate thyroid fine-needle aspirate biopsies. Ann Surg Oncol. 2011; 18: 2893-2898.
32. Marchetti I, Lessi F, Mazzanti CM, et al. A morpho-molecular diagnosis of papillary thyroid carcinoma: BRAF V600E detection as an important tool in preoperative evaluation of fine-needle aspirates. Thyroid. 2009; 19: 837-842.
33. Riesco-Eizaguirre G, Gutiérrez-Martínez P, Garcia-Cabezas MA, Nistal M, Santisteban P,. The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane. Endocr Relat Cancer. 2006; 13: 257-269.
34. Vanderlaan PA, Marqusee E, Krane JF,. Features associated with locoregional spread of papillary carcinoma correlate with diagnostic category in the Bethesda System for reporting thyroid cytopathology. Cancer Cytopathol. 2012; 120: 245-253.
35. Monchik JM, Simon CJ, Caragacianu DL, et al. Does failure to perform prophylactic level VI node dissection leave persistent disease detectable by ultrasonography in patients with low-risk papillary carcinoma of the thyroid? Surgery. 2009; 146: 1182-1187.
36. Perrino M, Vannucchi G, Vicentini L, et al. Outcome predictors and impact of central node dissection and radiometabolic treatments in papillary thyroid cancers < or =2 cm. Endocr Relat Cancer. 2009; 16: 201-210.
37. Moo TA, McGill J, Allendorf J, Lee J, Fahey T 3rd, Zarnegar R,. Impact of prophylactic central neck lymph node dissection on early recurrence in papillary thyroid carcinoma. World J Surg. 2010; 34: 1187-1191.
38. Hughes DT, White ML, Miller BS, Gauger PG, Burney RE, Doherty GM,. Influence of prophylactic central lymph node dissection on postoperative thyroglobulin levels and radioiodine treatment in papillary thyroid cancer. Surgery. 2010; 148: 1100-1106.
39. So YK, Seo MY, Son YI,. Prophylactic central lymph node dissection for clinically node-negative papillary thyroid microcarcinoma: influence on serum thyroglobulin level, recurrence rate, and postoperative complications. Surgery. 2012; 151: 192-198.